HC Wainwright & Co. Maintains Buy on MediWound, Raises Price Target to $28
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Swayampakula Ramakanth has reaffirmed a Buy rating on MediWound (NASDAQ:MDWD) and increased the price target from $26 to $28.
January 16, 2024 | 12:28 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
MediWound's stock may see a positive short term impact due to HC Wainwright's maintained Buy rating and raised price target from $26 to $28.
Analyst ratings and price target adjustments are significant indicators for investors. The increase in price target by HC Wainwright suggests a positive outlook on MediWound's performance, which can lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100